Skip to main content
OpenTrials
Completed

NCT Number: NCT01443520

Effect of Duloxetine and Venlafaxine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol: A Three-phase Randomized Balanced Cross-over Study in Healthy Volunteers

Tramadol is an opioid analgesic, which is widely used in the treatment of acute and neuropathic pain. After oral administration, tramadol is rapidly and almost completely absorbed. Tramadol is extensively metabolised by O- and N-demethylation, which are catalysed by the liver CYP-450 enzymes. O-desmethyltramadol is an active metabolite and its formation is catalysed by CYP2D6. This study is aimed to investigate the possible interaction of oral tramadol with duloxetine and venlafaxine. Duloxetine is known to inhibit CYP2D6. Twelve healthy male or female adult non-smoking volunteers aged 18-40 years with body weights within ±15% of the ideal weight for height are taken into the study. Primary endpoints of the study are plasma concentrations of tramadol and its metabolites.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital

Turku, Finland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • Age 18-40
  • Body weight within ±15% of the ideal weight for height

Exclusion criteria

  • A previous history of intolerance to the study drugs or to related compounds and additives
  • Concomitant drug therapy of any kind for at least 14 days prior to the study
  • Existing or recent significant disease
  • History of hematological, endocrine, metabolic or gastrointestinal disease, including gut motility disorders
  • History of asthma or any kind of drug allergy
  • Previous or present alcoholism, drug abuse, psychological or other emotional problems that are likely to invalidate informed consent, or limit the ability of the subject to comply with the protocol requirements
  • A positive test result for urine toxicology
  • A "yes" answer to any one of the Abuse Questions
  • Pregnancy or nursing
  • Donation of blood for 4 weeks prior and during the study
  • Special diet or life style conditions which would compromise the conditions of the study or interpretation of the results
  • Participation in any other studies involving investigational or marketed drug products concomitantly or within one month prior to the entry into this study
  • Smoking for one month before the start of the study and during the whole study period
  • Any history of coagulation abnormality, also in first degree relatives

Treatment and study plan

Placebo

Drug

The subjects will be given orally placebo twice a day for 8 days prior to the study.

Duloxetine

Drug

The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.

Venlafaxine

Drug

The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.

Primary outcomes

  1. Concentration of tramadol and its metabolites in plasma

    Time frame: 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hours after administration of tramadol

Secondary outcomes

  1. Serotonin concentrations

    Time frame: 0, 4 and 8 hours after tramadol administration

    Serotonin concentrations will be analyzed with chromatographical methods from the blood samples drawn 0, 4 and 8 hours after tramadol administration

  2. Pharmacodynamic effects

    Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12 hours after administration of tramadol

    The psychomotor effects of tramadol will be assessed with the measurement of pupil size with Cogan's pupillometer, Maddox wing test and digit symbol substitution test

  3. Analgesia

    Time frame: 1, 2, 3, 4, 5, 6, 8, 10, 12 hours after the administration of tramadol

    The analgesic effect of tramadol will be evaluated using the cold pressor test. Briefly, the subject's hand is immersed into ice-cold water of + 4° C up to the wrist. The subject is told to keep his or her hand in the water and to report when the cold sensation becomes painful. Cold pain threshold is defined as the latency from the immersion of the hand to the subject's first report of pain. Cold pain intensity is assessed at 30 s intervals following immersion of the hand in cold water for up to 60s . A verbal numerical rating scale of 0-100 will be used.

Sponsors and collaborators

Lead sponsor

Turku University Hospital

Other Gov

Registry information

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Sep 29, 2011
Registry last updated
May 22, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.